Pharmacogenomics

Article	Citations
Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience	37
Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?	31
Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment	26
Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy	25
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry	25
Assessment of primary care practitioners’ attitudes and interest in pharmacogenomic testing	22
The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis	22
Are pharmacists from the province of Quebec ready to integrate pharmacogenetics into their practice	22
PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing	21
The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review	20
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention	19
Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study	18
Potential of whole-genome sequencing-based pharmacogenetic profiling	18
Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs	17
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective	17
Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors	16
Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program	16
PGxKnow: a pharmacogenomics educational HoloLens application of augmented reality and artificial intelligence	16
Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly	15
Pharmacogenomics in the UK National Health Service: opportunities and challenges	15
Pharmacogenomics of oxycodone: a narrative literature review	14
Pharmacogenomics of methadone: a narrative review of the literature	14
Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-an	14
Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese	13
Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models	13

NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia	12
ATP binding cassette transporters and cancer: revisiting their controversial role	12
CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls	12
Providers’ perspectives on the clinical utility of pharmacogenomic testing in pediatric patients	12
ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations	11
An assessment of patient perspectives on pharmacogenomics educational materials	11
Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics	11
Pharmacogenomics education, research and clinical implementation in the state of Minnesota	11
Pharmacotherapies and personalized medicine for alcohol use disorder: a review	10
Evaluating the current level of pharmacists’ pharmacogenomics knowledge and its impact on pharmacogenomics implementation	10
Developing a gene panel for pharmacoresistant epilepsy: a review of epilepsy pharmacogenetics	10
Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes	10
The pharmacogenetics of treatment with olanzapine	10
The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis	9
Impact of variants in ATP-binding cassette transporters on breast cancer treatment	9
Variant discovery using next-generation sequencing and its future role in pharmacogenetics	9
Pharmacogenomics in psychiatry – the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing	9
Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients	9
Pharmacogenetics of inflammatory bowel disease	8
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium	8
Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation	8
Gender-dependent association ofTYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity	8
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis	8
The effects of sex on pharmacogenetically guided drug treatment	8
Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis	8
Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists	8
Substrate specificity of CYP2D6 genetic variants	8
Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics	8
Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report	8
PARC report: a perspective on the state of clinical pharmacogenomics testing	8
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy	8
miRNAs as potential biomarkers of treatment outcome in rheumatoid arthritis and ankylosing spondylitis	7
NAMPTsingle-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia	7
Association of NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy	7
Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges	7
Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns	7
lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis	7
The need to shift pharmacogenetic research from candidate gene to genome-wide association studies	7
Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients	7
Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia	7
Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison	7
Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis	7
Fibrate pharmacogenomics: expanding past the genome	7
Patients’ perspectives of a pharmacist-provided clinical pharmacogenomics service	7
Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study	6
Pharmacogenetics of anxiety and depression in Alzheimer's disease	6
Progression of precision statin prescribing for reduction of statin-associated muscle symptoms	6
Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury	6
The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?	6
Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?	6

The promise of digital health in healthcare equity and medication adherence in the disadvantaged dementia population	6
HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity	6
Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population	6
Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms	6
PARC report: health outcomes and value of personalized medicine interventions: impact on patient care	6
Personal genotyping and student outcomes in genetic and pharmacogenetic teaching: a systematic review and meta-analysis	6
Genetic variation in Charcot–Marie–Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy	6
The importance of phenoconversion when using the CYP2D6 genotype in clinical practice	6
Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers	6
The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing	6
Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate	6
The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis	6
Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews	6
Noncoding SNPs associated with increased GDF15 levels located in a metformin-activated enhancer region upstream of GDF15	6
KRAS-targeted therapies in advanced solid cancers: drug the undruggable?	5
Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites	5
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients	5
Phenylethanolamine N-methyltransferase gene polymorphisms associate with crisis pain in sickle cell disease patients	5
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events	5
The association betweenHLA-B*15:02and phenytoin-induced severe cutaneous adverse reactions: a meta-analysis	5
Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder	5
Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate	5
CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research	5
Adolescent perceptions of pharmacogenetic testing	5
Implementation of a pharmacogenomic program in a Brazilian public institution	5
Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population	5
A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters	5
Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer	5
PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case–control genome-wide study	5
Pharmacogenomics education and perceptions: is there a gap between internal medicine resident and attending physicians?	5
Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia	5
Methods for actionable gene fusion detection in lung cancer: now and in the future	5
Healthcare professionals' knowledge, confidence and perceptions of pharmacogenomics in primary care and pain management	5
Pharmacogenomics and prescription opioid use	5
Clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients	5
Malignant hyperthermia susceptibility: utilization of genetic results in an electronic medical record to increase safety	5
Integrating pharmacogenetic testing via medication therapy management in an outpatient family medicine clinic	5
Polymorphisms in theCYP3A5gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation	5
Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?	5
Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage	5
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?	5
Pharmacogenetic differentiation across Latin America	5
Efficacy and safety of opioid therapy guided by pharmacogenetics: a systematic review	5
Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk	5
Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies	5
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?	5
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes	5
Pharmacogenetic testing in psychiatry and neurology: an overview of reviews	4
HLA-A*24:07as a potential biomarker for carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in Filipino patients	4
CYP2C18: the orphan in the CYP2C family	4
Predictive values of colon microbiota in the treatment response to colorectal cancer	4
AGO2 expression levels and related genetic polymorphisms: influence in renal cell progression and aggressive phenotypes	4
Association between genetic polymorphism and antidepressants in major depression: a network meta-analysis	4
Pharmacogenetics and statin-related myopathy: what do we know?	4
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety	4
KCNQ1 variant rs163184 is a potential biomarker of glycemic response to exenatide	4
Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype	4
Role of miRNA gene variants in the susceptibility and pharmacogenetics of colorectal cancer	4
Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice	4
Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters	4
Prioritizing rs7294 as a mirSNP contributing to warfarin dosing variability	4
The pharmacogenomics of selective serotonin reuptake inhibitors	4
Clinical pharmacogenomics implementation in Thailand: a dream come true	4
Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children	4
Pharmacogenetics studies in stroke patients treated with rtPA: a review of the most interesting findings	4
Engaging pharmacogenomics in pain management and opioid selection	4
Case report: severe toxicity in an African–American patient receiving FOLFOX carrying uncommon allelic variants in DPYD	4
DPYDgenotyping and predicting fluoropyrimidine toxicity: where do we stand?	4
The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing	4
Pharmacogenetic associations and evidence-based pharmacogenomics guidelines: supporting label and off-label use of drug–gene interaction data	4
DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells	4
Sociodemographic factors and beliefs about medicines in the uptake of pharmacogenomic testing in older adults	4
Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation	4
Evaluation of a longitudinal pharmacogenomics education on pharmacist knowledge in a multicampus healthcare system	4
Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity	4
Liver enzyme CYP2D6 gene and tardive dyskinesia	4
CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study	3
Aggressive prostate cancer phenotype and genome-wide association studies: where are we now?	3
Impact of genetic polymorphisms on tacrolimus trough blood concentration in Chinese liver transplant recipients	3
Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamide regimen in breast cancer patients	3

Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema	3
Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma	3
Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10	3
The role of alcohol intake in the pharmacogenetics of treatment with clozapine	3
Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system	3
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score	3
Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients	3
Genetic variants ofPEAR1 and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis	3
The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants	3
Use of a consultation service following pharmacogenetic testing in psychiatry	3
Attitudes about pharmacogenomic testing vary by healthcare specialty	3
Head-to-head comparison of various antipsychotic agents on genome-wide methylation in schizophrenia	3
Pharmacogenomics and clinical cultural competency: pathway to overcome the limitations of race	3
High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients	3
Pan-cancer pharmacogenetics: targeted sequencing panels or exome sequencing?	3
Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects	3
miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3	3
Genetics and immunological recovery with antiretroviral treatment for HIV	3
Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison	3
The role of pharmacogenomics in the personalization of Parkinson's disease treatment	3
Effects of EPHX1 rs2260863 polymorphisms on warfarin maintenance dose in very elderly, frail Han-Chinese population	3
Allopurinol-induced severe cutaneous adverse reactions in Vietnamese: the role of HLA alleles and other risk factors	3
Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations	3
Identification of rare defective allelic variants in cases of thiopurine S-methyltransferase deficient activity	3
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile	3
Implementation of pharmacogenomics in product information	3
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer	2
Effect of CYP3A5*3 genotypes on lumefantrine plasma concentrations among malaria-HIV-infected women	2
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer	2
Pharmacogenetics and tacrolimus administration in stem cell transplantation	2
Pharmacogenomics testing in patients with liver transplant and potential impact on prospective management	2
Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events	2
Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran	2
Knowledge and attitudes of incoming pharmacy students toward pharmacogenomics and survey reliability	2
Breast cancer pharmacogenetics: a systematic review	2
Pharmacoepigenomics: a key determinant in resolving epigenomic parameters in pathogenesis and treatment response in complex diseases	2
Gene-wise variant burden and genomic characterization of nearly every gene	2
Indo–Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine	2
Gene expression profiling in allopurinol-induced severe cutaneous adverse reactions in Vietnamese	2
Association of polymorphisms in ARRB2 and clinical response to methadone for pain in advanced cancer	2
Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches	2
Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis	2
Pharmacogenetic testing-guided treatment for oncology: an overview of reviews	2
Extending the lymphoblastoid cell line model for drug combination pharmacogenomics	2
The importance of including African populations in pharmacogenetics studies of warfarin response	2
ABCB1 and OPRM1 single-nucleotide polymorphisms collectively modulate chronic shoulder pain and dysfunction in South African breast cancer survivors	2
NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity	2
Use of pharmacogenetics for benzodiazepine prescription: state of the art and expectations	2
Polymorphisms of genes related to phase II metabolism and resistance to clopidogrel	2
Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants	2
Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa	2
The search for personalized antidepressant treatments: what have we learned and where are we going	2
Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus	2
Building an information system to facilitate pharmacogenomics clinical translation with clinical decision support	2
Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report	2
Interethnic differences in drug response: projected impact of genetic variations in the Saudi population	2
Keeping pace with CYP2D6 haplotype discovery: innovative methods to assign function	2
Pharmacogenetics: ethnicity, treatment and health in Latin American populations	2
Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?	2
Impact of the PEAR 1 polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention	2
Pilot study of multi-gene pharmacogenetic testing for pain management in oncology palliative medicine	2
YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients	2
Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response	2
Ending the pharmacogenomic gag rule: the imperative to report all results	2
Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in China	2
A single-tube multiplex real-time PCR for HLA-B*38:02 genotype by detecting highly specific SNPs	2
DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses	2
Systematic review of Pharmacogenomics Knowledgebase evidence for pharmacogenomic links to the dopamine reward pathway for heroin dependence	2